AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$LIVN

LivaNova PLC (LIVN) (Q3 2026) Earnings Call Highlights: Double-Digit Growth Fuels

LivaNova PLC (LIVN) reported Q3 2026 earnings with adjusted free cash flow declining to $56M from $62M YoY. SG&A expenses rose to $136M from $123M, and a $400M payment shifted to Q4, creating cash flow uncertainty. The company expects 1% FX tailwind but $5M tariff headwinds. Cardiopulmonary growth remains strong, with double-digit increases, and the next-gen oxygenator launch is on track for 2028.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 1:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
LivaNova PLC (LIVN) (Q3 2026) Earnings Call Highlights: Double-Digit Growth Fuels — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LIVNNeutralMed
01

Why it matters

The mixed financial signals may cause short‑term volatility while the growth outlook sustains longer‑term interest.

02

Market read

Earnings‑call details provide new data for traders evaluating med‑tech exposure.

03

What to watch

The upcoming CPT code changes in 2028 and the Thermo Fisher component agreement could unlock additional upside not reflected in current pricing.

Relevance 7/10Novelty 6/10Timing: post‑earnings Q3 2026 release

Background

LivaNova's Q3 2026 earnings call highlighted double‑digit growth but disclosed weaker cash flow and a delayed SNIA payment.

Company-level read

Ticker impact

$LIVNNeutralHigh confidence
Context

Adjusted free cash flow fell to $56M YoY and a $400M SNIA payment was delayed to Q4, indicating near‑term cash pressure despite double‑digit growth guidance.

Expected impact

likely modest downside as investors price cash‑flow weakness, offset by upbeat growth guidance

Evidence & confidence

The article provides fresh earnings‑call numbers and guidance changes that were not previously public.

Market effects

Sector

Signals potential cash‑flow constraints for other cardiopulmonary device makers facing similar payment timing issues.

Regional

US‑based investors may reassess short‑term exposure to med‑tech stocks.

Global

Limited to the niche OSA device market; broader market impact minimal.

Counterpoint

What could challenge this read

Investors could view the cash‑flow dip as a temporary blip and buy on the long‑term growth narrative.

Key entities

  • Company
    LivaNova PLC

    Medical device maker focused on cardiopulmonary and neurostimulation products.

Read at source← All news

StoryLivaNova posts Q3 2026 earnings beat and lifts full‑year revenue and EPS guidance

Also covered by

6 outlets

Related articles

$LIVNMed

LivaNova PLC Q3 2026 Earnings Call Summary

LivaNova PLC raised its full-year 2026 revenue guidance to 9-10% growth and adjusted EPS to $4.40-$4.50. Growth was driven by record Essence heart-lung machine placements, epilepsy volume growth, and reduced discounting. The company plans to enter the obstructive sleep apnea (OSA) market in 2027 and expects double-digit capacity expansion in 2027 due to new manufacturing lines. Management highlighted strong demand for oxygenators and strategic initiatives to support future growth.

finance.yahoo.com
$LIVNMed

Mizuho raises Livanova stock price target on Essenz placements

Mizuho raised its price target for Livanova (LIVN) to $115 from $95, citing strong U.S. Cardiopulmonary segment growth and Essenz placements. The stock has risen 48% in the past year, trading at $96.59. Livanova reported Q3 2026 earnings of $1.23 per share, beating estimates, and raised its full-year outlook. Jefferies also increased its price target to $120.

investing.com
$LIVNHighAI 8/10

Jefferies raises Livanova stock price target to $120 on guidance

Jefferies increased its price target for LivaNova (NASDAQ:LIVN) to $120 from $100, maintaining a Buy rating. The company reported Q3 sales of $393M, up 10%, and EPS of $1.23, up 20%, both beating estimates. LivaNova raised its full-year sales growth guidance to 9-10% and EPS guidance to $4.40-$4.50. The stock has a market cap of $5.33B and a PEG ratio of 0.12, according to InvestingPro.

investing.com